Pacer Advisors Inc. Sells 7,951 Shares of Moderna, Inc. (NASDAQ:MRNA)

Pacer Advisors Inc. trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 14.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,392 shares of the company’s stock after selling 7,951 shares during the period. Pacer Advisors Inc.’s holdings in Moderna were worth $4,514,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. grew its position in Moderna by 2.7% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 58,338 shares of the company’s stock worth $5,802,000 after acquiring an additional 1,554 shares in the last quarter. Compagnie Lombard Odier SCmA boosted its holdings in shares of Moderna by 5.1% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 136,593 shares of the company’s stock worth $13,584,000 after buying an additional 6,616 shares during the period. CX Institutional bought a new stake in shares of Moderna during the 4th quarter worth $236,000. Jeppson Wealth Management LLC bought a new stake in shares of Moderna during the 4th quarter worth $228,000. Finally, DMC Group LLC boosted its holdings in shares of Moderna by 13.7% during the 4th quarter. DMC Group LLC now owns 7,716 shares of the company’s stock worth $767,000 after buying an additional 927 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Trading Down 3.6 %

Shares of MRNA stock opened at $106.56 on Friday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $163.24. The stock has a market cap of $40.80 billion, a price-to-earnings ratio of -8.59 and a beta of 1.60. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The firm has a fifty day moving average of $98.94 and a 200-day moving average of $93.58.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same quarter in the prior year, the firm earned $3.61 EPS. The firm’s quarterly revenue was down 44.9% compared to the same quarter last year. On average, equities research analysts forecast that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the subject of several recent analyst reports. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a report on Tuesday, January 2nd. Canaccord Genuity Group upped their price objective on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. JPMorgan Chase & Co. decreased their price objective on shares of Moderna from $93.00 to $90.00 and set a “neutral” rating for the company in a report on Friday, December 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Moderna in a research note on Thursday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $129.82.

Insider Transactions at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $102.39, for a total value of $1,535,850.00. Following the sale, the director now owns 2,116,931 shares of the company’s stock, valued at approximately $216,752,565.09. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the sale, the insider now owns 9,267 shares in the company, valued at approximately $917,896.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $102.39, for a total transaction of $1,535,850.00. Following the completion of the sale, the director now owns 2,116,931 shares of the company’s stock, valued at approximately $216,752,565.09. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,021 shares of company stock valued at $5,211,442. 15.70% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.